CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Optical coherence tomography is a kid on the block: I would choose intravascular ultrasound A systematic review of factors predicting door to balloon time in ST-segment elevation myocardial infarction treated with percutaneous intervention Biological Phenotypes of Heart Failure With Preserved Ejection Fraction Correlation and prognostic role of neutrophil to lymphocyte ratio and SYNTAX score in patients with acute myocardial infarction treated with percutaneous coronary intervention: A six-year experience Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial Pharmacoinvasive and Primary Percutaneous Coronary Intervention Strategies in ST-Elevation Myocardial Infarction (from the Mayo Clinic STEMI Network) Symptom onset-to-balloon time and mortality in the first seven years after STEMI treated with primary percutaneous coronary intervention Oxygen Therapy in Suspected Acute Myocardial Infarction Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting

Review Article2013 Dec 24;62(25 Suppl):D34-41.

JOURNAL:J Am Coll Cardiol. Article Link

Updated clinical classification of pulmonary hypertension

Simonneau G, Gatzoulis MA, Adatia I et al. Keywords: CHD; HAART; HIV; IFN; PAH; PAP; PH; PH due to chronic lung diseases; PH due to left heart disease; POPH; PPHN; PVR; SCD; Sch-PAH; TGF; TKI; chronic thromboembolic pulmonary hypertension; congenital heart disease; highly active antiretroviral therapy; human immunodeficiency virus; interferon; persistent pulmonary hypertension of the newborn; portopulmonary hypertension; pulmonary arterial hypertension; pulmonary arterial pressure; pulmonary hypertension; pulmonary vascular resistance; schistosomiasis-associated PAH; sickle cell disease; tumor growth factor; tyrosine kinase inhibitor

FULL TEXT PDF